Welcome to our dedicated page for BillionToOne news (Ticker: BLLN), a resource for investors and traders seeking the latest updates and insights on BillionToOne stock.
BillionToOne, Inc. (NASDAQ: BLLN) is a Menlo Park, California-based molecular diagnostics company that regularly issues news about its prenatal and oncology testing portfolio, technology platform, collaborations, and financial performance. The company’s public updates frequently highlight developments related to its Quantitative Counting Templates (QCT) molecular counting platform and its clinical tests.
News about BillionToOne often covers clinical and technology milestones for its key products. In prenatal health, the company reports on the use and capabilities of its UNITY Complete non-invasive prenatal test, which it describes as providing direct fetal risk assessment for multiple recessive and X-linked conditions and aneuploidies from a single maternal blood sample. In oncology, updates focus on the Northstar Select and Northstar Response liquid biopsy tests, including data on sensitivity, clinical validation, and use in therapy selection and treatment monitoring.
Investors and clinicians can also find announcements about research collaborations and clinical studies. For example, BillionToOne has reported that Northstar Select was chosen as the liquid biopsy platform for the LC-SCRUM-TRY-Japan study at the National Cancer Center Hospital East, a nationwide effort to better understand drug-resistant non-small cell lung cancer. The company has also announced a collaboration with Epic to integrate UNITY Complete and Northstar tests into Epic’s Aura diagnostics suite, enabling ordering and results delivery within the electronic health record.
In addition, BillionToOne issues press releases on financial results, revenue guidance, and capital markets activities, including its initial public offering on the Nasdaq Global Select Market. Visitors to this news page can review company communications on clinical performance, partnerships, and corporate developments related to BLLN.
BillionToOne (NASDAQ: BLLN) announced a collaboration with Epic to integrate its prenatal and oncology tests into Epic's Aura diagnostics suite. The agreement, signed in December 2025, enables clinicians to order UNITY Complete prenatal testing and Northstar Select and Northstar Response liquid biopsy tests directly in Epic, with discrete results flowing back into the EHR and MyChart. The integration aims to simplify ordering, speed clinical decision making, and improve the patient and provider experience across health systems, maternal-fetal medicine, and oncology settings.
BillionToOne (NASDAQ: BLLN) reiterated full year 2025 guidance of $293 million to $299 million and initiated full year 2026 guidance of $415 million to $430 million, implying ~40%–45% revenue growth versus the midpoint of 2025 guidance. The company guided to positive GAAP operating income for both the remainder of 2025 (reiterated) and for full year 2026. Management cited a roadmap to scale its molecular diagnostics platform and deliver a durable, high-quality growth profile in 2026.
BillionToOne (NASDAQ: BLLN) announced that its Northstar Select liquid biopsy was selected as the new plasma-based genomic test for LC-SCRUM-TRY (Japan) at National Cancer Center Hospital East, effective November 2025. The platform uses single-molecule NGS with QCT technology and, per a peer-reviewed prospective head-to-head study, achieved the highest sensitivity among evaluated commercial assays and a 95% LoD down to 0.15% variant allele frequency. The test also met Palmetto GBA MolDx Medicare coverage criteria.
BillionToOne (NASDAQ: BLLN) announced management will participate in the 44th Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Monday, January 12, 2026, from 9:45 AM to 10:25 AM PT. A live and archived webcast will be available on BillionToOne's Events & Presentations investor page at https://investors.billiontoone.com/news-events/events-presentations.
BillionToOne (NASDAQ: BLLN) announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026, and named him Chair of the Audit Committee.
Pagano is currently CFO and Executive Vice President of Genmab since March 2020 and previously joined Genmab in December 2007. During his tenure at Genmab, annual revenues grew from $100M to more than $3B. He began his career at KPMG, served in senior finance roles at NovaDel Pharma, is a Certified Public Accountant, holds a B.S. in Accounting and an M.B.A. from NYU Stern.
Company leaders said Pagano's financial experience will support BillionToOne's growth and governance as it advances its molecular diagnostics strategy.
BillionToOne (NASDAQ: BLLN) reported strong third-quarter 2025 results and issued full-year guidance. Total revenue was $83.5M in Q3 2025, up 117% year-over-year; prenatal revenue was $74.1M (+102%) and oncology revenue was $8.7M (+664%).
Gross margin improved to 70% (vs. 53% prior year); operating income was $9.6M and net income available to common shareholders was $1.5M ($0.10 diluted). The company accessioned 162,900 tests in Q3 and delivered 165,000 tests.
Company raised $314.0M gross proceeds in its IPO and ended September 30, 2025 with approximately $195.2M cash. BillionToOne expects 2025 revenue of $293M–$299M and positive GAAP operating income for Q4 and full-year 2025.
BillionToOne (NASDAQ: BLLN) will release financial results for the third quarter ended September 30, 2025 after market close on Tuesday, December 9, 2025. The company will host a conference call to discuss results at 1:30 PM PT / 4:30 PM ET the same day.
Investors must register to participate in the call before the start time. A live and archived webcast will be available on the company’s Events page at https://investors.billiontoone.com/.
BillionToOne (NASDAQ: BLLN) closed an upsized initial public offering on Nov 7, 2025, selling 5,233,765 shares of Class A common stock, which includes full exercise of the underwriters’ option for an additional 682,665 shares.
The public offering price was $60.00 per share, and the aggregate gross proceeds were approximately $314.0 million before underwriting discounts, commissions and estimated offering expenses. BillionToOne began trading on the Nasdaq Global Select Market on Nov 6, 2025 under the ticker BLLN.
BillionToOne (Nasdaq: BLLN) completed an upsized initial public offering of 4.6 million shares of Class A common stock at $60 per share, generating approximately $273.1 million in aggregate gross proceeds. The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025.
Gunderson Dettmer represented BillionToOne across multiple financings from Series A through late-stage rounds and advised on the public listing; J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers, with Stifel, Wells Fargo Securities and BTIG also serving as book-running managers.
BillionToOne (Nasdaq: BLLN) priced an upsized initial public offering of 4,551,100 shares of Class A common stock at $60.00 per share, with expected gross proceeds of approximately $273.1 million before underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 682,665 shares at the IPO price. Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
FAQ
What is the current stock price of BillionToOne (BLLN)?
What is the market cap of BillionToOne (BLLN)?
